Well, here is something with more direct relevance:
>>Bioorg Med Chem. 2003 Aug 15;11(17):3695-707.
Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries.
Ferraris D, Ficco RP, Dain D, Ginski M, Lautar S, Lee-Wisdom K, Liang S, Lin Q, Lu MX, Morgan L, Thomas B, Williams LR, Zhang J, Zhou Y, Kalish VJ.
Guilford Pharmaceuticals Inc., 6611 Tributary Street, Baltimore, MD 21224, USA. ferrarisd@guilfordpharm.com
A class of poly(ADP-ribose) polymerase (PARP-1) inhibitors, the imidazobenzodiazepines, are presented in this text. Several derivatives were designed and synthesized with ionizable groups (i.e., tertiary amines) in order to promote the desired pharmaceutical characteristics for administration in ischemic injury. Within this series, several compounds have excellent in vitro potency and our computational models accurately justify the structure-activity relationships (SARs) and highlight essential hydrogen bonding residues and hydrophobic pockets within the catalytic domain of PARP-1. Administration of these compounds (5q, 17a and 17e) in the mouse model of streptozotocin-induced diabetes results in maintainance of glucose levels. Furthermore, one such inhibitor (5g, IC(50)=26 nM) demonstrated significant reduction of infarct volume in the rat model of permanent focal cerebral ischemia.<<
Cheers, Tuck |
